The answer so far

Ipamorelin and MK-677 (ibutamoren) are different substances that can activate the ghrelin receptor and stimulate growth-hormone release. Ipamorelin is a peptide; MK-677 is a small molecule, not a SARM. Their human studies asked different questions, so they cannot tell us which is better for muscle, sleep or fat loss.43

On this page
  1. Why are these names grouped together?
  2. What is the shared signal?
  3. What has ipamorelin been studied for in people?
  4. What did the MK-677 body-composition study find?
  5. Will both make someone hungrier or burn fat?
  6. What about side effects and uncertainty?
  7. Are a tablet and a vial equivalent?
  8. Does combining them or adding CJC-1295 help?
  9. What if I compete in sport?
  10. Sources
Follow this question
Ipamorelin and MK-677: are they the same kind of growth-hormone signal? Choose a step to explore this subject in more detail.
  1. 1Why are these names grouped together?
  2. 2What is the shared signal?
  3. 3What has ipamorelin been studied for in people?
  4. 4What did the MK-677 body-composition study find?

Why are these names grouped together?

Ipamorelin is a short synthetic peptide. Ibutamoren, also called MK-677, is a non-peptide small molecule; despite sometimes being sold alongside SARMs, it is not a SARM. Both are called growth-hormone secretagogues because they can stimulate the body to release growth hormone. That label explains an intended action, not that the two products have the same effects or approval. Follow the individual profiles for ipamorelin and MK-677.45

What is the shared signal?

Ghrelin is a natural messenger involved in hunger and other processes. Its receptor is a signalling switch found in several tissues, including parts of the brain and pituitary, the gland beneath the brain that releases growth hormone. Ipamorelin and ibutamoren can activate this receptor; the resulting growth-hormone signal can influence IGF-1, another messenger. A receptor is not an outcome: changes in its activity or a blood level do not directly measure stronger muscles, better sleep or a healthier life. See the growth-hormone story in plain language.13

One signal, different questionsThese studies are separate; their results are not a head-to-head comparison.
  • Shared receptorBoth can activate the ghrelin receptor and stimulate growth-hormone release.
  • IpamorelinA peptide studied briefly for hormone response and separately after bowel surgery.
  • MK-677A small molecule studied in older adults for fat-free mass and other outcomes.
  • Still to establishWhich, if either, improves muscle strength, sleep or fat loss in a given population.

What has ipamorelin been studied for in people?

One short study gave healthy male volunteers an intravenous ipamorelin preparation and measured how its concentration and growth-hormone levels changed. It observed a hormone-release peak, not muscle growth or better sleep. The abstract describes eight people at each of five study levels. FDA’s later presentation gives a different total, so the exact number enrolled is uncertain here. A separate 2014 trial in hospital patients after bowel surgery compared intravenous ipamorelin with placebo: 117 enrolled and 114 were analysed. The difference in time to tolerate a meal was not statistically significant. Neither study compared it with MK-677.142

What did the MK-677 body-composition study find?

In a separate trial, 71 healthy adults aged 60–81 were randomised to oral MK-677 or placebo; 65 completed the first year. Mean fat-free mass rose by 1.1 kg with MK-677 and fell by 0.5 kg with placebo. Fat-free mass includes water and tissues other than muscle, and the trial did not demonstrate a corresponding improvement in measured strength or function; it was too small to settle functional effects. There was no statistically significant difference in total or abdominal visceral fat. NIH and other grants supported the work, Merck supplied the study product and placebo, and authors disclosed company ties. These are group results in older adults, not a head-to-head comparison with ipamorelin.3

Will both make someone hungrier or burn fat?

Not necessarily. Increased appetite was reported in the MK-677 older-adult trial; the authors said the increase tended to subside after a few months. That does not establish that every person has the same experience or that ipamorelin causes the same appetite change. A rise in growth hormone also does not prove a lasting reduction in body fat. For the different meanings of appetite, fat burning and weight loss, see the weight-loss peptide guide.35

What about side effects and uncertainty?

In the MK-677 study, average fasting glucose rose and insulin sensitivity fell; appetite increase, swelling in the lower legs and muscle pain were reported. FDA warns that ibutamoren may cause fluid retention and glucose changes, among other risks, and says it is not FDA approved. For ipamorelin, FDA discussed two deaths after complications in the bowel-surgery trial but said the relationship to the drug was unclear. Neither finding establishes the other substance’s risk rate. These studies are too different to rank overall safety; a clinician can assess symptoms and the complete product and medicine history.345

Are a tablet and a vial equivalent?

No. The MK-677 study used an oral investigational preparation; the ipamorelin studies described above used intravenous preparations. A substance’s route changes how and where the body is exposed, and a seller’s label does not establish the identity, strength or sterility of an online product. FDA’s 2024 briefing identified a lack of human safety data for the proposed under-the-skin ipamorelin forms it evaluated. That does not tell us the safety of every possible formulation. See what a certificate of analysis can show.45

Does combining them or adding CJC-1295 help?

A shared receptor does not establish that combining these substances improves results or is safe. CJC-1295 is discussed through a different growth-hormone-releasing signal, but that rationale is not proof of a benefit from a combination. We did not identify a direct ipamorelin-versus-MK-677 comparison in the sources checked; cross-study differences cannot establish which gives more muscle, less fat or better sleep. Read CJC-1295 and ipamorelin compared.43

What if I compete in sport?

For athletes subject to the World Anti-Doping Code, the 2026 WADA list names both ipamorelin and ibutamoren among growth-hormone secretagogues prohibited in and out of competition. Rules, dates and therapeutic-use processes depend on the athlete and authority. Check the applicable current list and speak with the relevant anti-doping organisation before making a decision; see how to check peptide and sport rules.6

Sources, kept close.

Selected supporting sources; this is not a complete literature review.

  1. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteersPharmaceutical Research / PubMed · Primary human pharmacology study, abstract; 1999Access checked 2026-11-06 · Brief IV exposure in healthy male volunteers, hormone response; abstract and FDA later summary report inconsistent participant totals.
  2. Ipamorelin for postoperative ileus in bowel resection patientsInternational Journal of Colorectal Disease / PubMed · Primary randomised placebo-controlled trial, abstract; 2014Access checked 2026-11-06 · 117 enrolled, 114 analysed; short IV hospital trial measuring meal tolerance, not muscle or sleep.
  3. Effects of an oral ghrelin mimetic on body composition in healthy older adultsAnnals of Internal Medicine / PubMed Central · Primary randomised placebo-controlled study, 2008Access checked 2026-11-06 · 71 randomised, 65 completed year 1; older adults, fat-free mass and visceral fat; Merck provided product and placebo; NIH and other grant funding, company affiliations disclosed.
  4. Ipamorelin: FDA advisory committee briefingUS Food and Drug Administration · US regulator assessment; 2024Access checked 2026-11-06 · Compounded formulations assessed; IV trial deaths of uncertain causality, and safety information gaps for proposed under-the-skin routes.
  5. Agebox iKids Growth Day Formula: hidden ibutamorenUS Food and Drug Administration · US product safety warning; 2025Access checked 2026-11-06 · Concern about one tested product and ibutamoren itself; FDA says ingredient not FDA approved and lists possible risks.
  6. World Anti-Doping Code: 2026 prohibited listWorld Anti-Doping Agency · International sport rules; 2026Access checked 2026-11-06 · S2 names ipamorelin and ibutamoren, prohibited at all times for covered athletes; check current list and applicable authority.

The next useful question.

Substance profile

Ipamorelin.

An evidence-gap guide to ipamorelin, a growth-hormone secretagogue marketed online despite limited route-specific human safety information.

4 min read